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Two vasopressin antagonists (‘vaptans’) are now in the
market for the treatment of euvolemic (Europe) or euvolemic
and hypervolemic (United States) hyponatremia: conivaptan
for intravenous use and tolvaptan for oral application.
Although their specificity and effectiveness are considered
established, their indications are not. At present, we do not
know which symptoms of hyponatremia and which degree of
hyponatremia should serve as indications for vaptans. Other
areas of uncertainty relate to the following unanswered
questions: do vaptans shorten the duration of
hospitalization? Is it justifiable to use them to prevent relapse
of hyponatremia in (chronic) SIAD(H)? (In this text we use the
abbreviation SIAD(H) instead of the recently proposed
abbreviation SIAD to emphasize that vaptans will work only
in the presence of ADH (‘SIADH’) but not in the syndrome of
nephrogenic antidiuresis.) Do they decrease the high
mortality associated with hyponatremia? How do we justify
the cost of chronic vaptan therapy? The optimal vaptan
regimen (dose, timing of controls) to treat SIAD(H) is
currently not established, as is the procedure to be
recommended in a too rapid correction rate of (chronic)
hyponatremia. Until these requirements shall be met by
additional studies, we are hesitant to consider vaptans a
treatment of choice for the appropriate hyponatremias.
Kidney International (2011) 80, 594–600; doi:10.1038/ki.2011.78;
published online 30 March 2011
KEYWORDS: conivaptan; hyponatremia; tolvaptan
Imagine for a moment that you were with a car dealer,
looking for a replacement of your ramshackle old model. The
dealer offers a great new—somewhat expensive—solar-driven
replacement. When you ask how (in which gear) to drive it,
where (on which type of road) to run it, and how much cost
you might incur from using that car, he would be vague,
unable to answer your questions precisely. Would you
consider that car? We would be very hesitant. We would
probably tell the dealer to come back later when he would be
certain of the answers. This we think is the situation of the
vaptans at present, as pointed out by others before.1
Hyponatremia has been known for some time as the most
frequent electrolyte disorder encountered.2,3 It is seen
primarily in hospitals, but it occurs in outpatients as well.3,4
Hyponatremia may cause symptoms and sometimes they are
as severe as coma and grand mal seizures.5 It has been shown
many times that hyponatremia is associated with increased
mortality.6–11 However, the therapy has been lagging behind.
Indirect measures such as (1) fluid restriction, (2) lithium
carbonate, (3) demeclocycline hydrochloride, (4) urea, (5)
3% saline, (6) loop diuretic in SIAD (syndrome of
inappropriate antidiuresis) and (7) CVVH (continuous
venovenous hemofiltration), or (8) SLED (sustained low-
efficiency dialysis) in select circumstances have all been
utilized for years. They have major drawbacks. Fluid
restriction (1) is often of limited effectiveness, although
physicians may not always try hard enough to implement it
or to convince the patient of its usefulness. Fluid restriction
in principle is promising in patients with a urinary osmolality
of o400–500 mOsm/kg, indicating that these patients
probably have a fluid intake in excess of 1.5 l/day. The other
measures are often unreliable and/or potentially toxic (3 and
4), not suitable for chronic outpatient therapy (5), too
cumbersome (6), or too invasive and expensive (7 and 8) for
everyday treatment of hyponatremia. Clearly then, there is an
unmet need for a specific, direct, easy, titratable therapy of
hyponatremia—something comparable with loop diuretic for
edematous disorders. Hence, it was considered a break-
through when vaptans, effective oral (tolvaptan12) or
parenteral (conivaptan13) antagonists of the hydroosmotic
effects of vasopressin in the kidney, met with regulatory
approval recently. Vaptans are now available in the drug
market. In phase II and III trials, vaptans have been shown to
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correct hyponatremia of euvolemic and hypervolemic states
effectively.12,14 Although this applies to scientific trials, the
question is of whether vaptans are really clinical therapeutic
breakthroughs as well.
In the following we shall discuss the role of vaptan
treatment in chronic but not acute hyponatremia because the
latter is rarely addressed in published literature. We shall
consider the hyponatremias of SIAD(H), cardiac failure, and
liver cirrhosis together—although vaptan treatment differs
somewhat between them—because reported vaptan trials did
not analyze these entities separately. However, we included a
table with an overview of the major vaptan trials to facilitate
finding more information pertaining to different indications
for the reader (Table 1).
THE INDICATIONS FOR VAPTANS ARE NOT CLEAR
In medical school, doctors are trained to treat patients—not
lab results on paper. Treatments are usually reserved for
symptomatic patients. In this field, vaptans let the physician
encounter a bunch of stumbling blocks:
First, we do not know how to distinguish between
symptoms that are an indication for vaptan and those that
are not. Given the high cost of vaptan therapy consider this:
would headache—when associated with hyponatremia—be
an indication for vaptan? Or what about the likes of
weakness, apathy, depressed mood, change of taste, or
reduced fine motor movements? There are no published
studies that evaluate the gain in quality of life from treating
such symptoms by vaptan vs their cost. In other words, we do
not know which symptoms are indications for vaptan
treatment.
Second, a given degree of chronic hyponatremia does not
necessarily cause comparable symptoms in different patients.
We (PAG) have recorded a patient with chronic hypoosmolar
hyponatremia of 109 mmol/l and no discernable symptoms at
the bedside, whereas others with chronic hypoosmolar
hyponatremia of ‘only’ 118 mmol/l were confined to bed,
unsteady, confused, and unable to concentrate. This brings
up two unanswerable questions:
(1) should we treat the patients at 118 mmol/l, but not the one
at 109 mmol/l, because of the clinical symptomatology?
(2) or, conversely, should we treat almost all hyponatremic
patients who are under 130 mmol/l, even if they appear
to be clinically asymptomatic? Renneboog et al.27 were
able to demonstrate neurocognitive defects literally in all
of them.26,27 These authors26 subjected 16 patients with
mild chronic hyponatremia of 128±3 mmol/l related to
SIAD(H) to formal testing before and after correction of
the hyponatremia. It was found that this mild hypona-
tremia reduced the tested abilities as follows: attention
(10% reduced), unsteadiness of gait (20% increased;
Figure 1), and total error rate (20% increased). Yet, the
findings of Renneboog et al.27 have not been translated
into a prospective study with clinical end points. We do
not know the meaning of the findings in real life. In the
same vein, the natural history of patients with severe
asymptomatic hyponatremia (arbitrarily defined here as
a serum sodium o120 mmol/l) has not been studied
either. We do not know their quality of life, their medical
complications, or their readmission rate to hospital
because of worsened hyponatremia. Together, we lack
information on which degree of severity of hyponatremia
should give us reason to consider vaptan treatment.
Third, work by Gankam Kengne et al.28 suggested that
patients with mild chronic hyponatremia fall to the ground
more often than matched normonatremic controls (see also
Figure 1). (In the present communication we arbitrarily
define mild hyponatremia as a serum sodium between 128
and 134 mmol/l.) They appeared to fracture a bone
approximately four times more often than their normona-
tremic counterparts. This was retrospective work.28 We do
not know if comparable results would hold up in a
prospective randomized controlled trial. We are unable to
answer the question of whether elderly patients with chronic
mild hyponatremia should be treated, for example, by a
vaptan to correct hyponatremia and prevent fractures.
Fourth, in terms of indication for vaptan, the area least
controversial might appear to be that of severe symptomatic
(chronic) hyponatremia. A ‘hyponatremia-naive’ physician is
likely to conclude that vaptans if anything should be
promising in severe symptomatic hyponatremia. However,
there are literally no published data on this. Clinical trials of
vaptans12,14,16,29 have consistently excluded severe sympto-
matic hyponatremia from study because of ethical concerns
(risk of worsening of severe symptoms when receiving
placebo). A recent expert panel suggested that in severe
symptomatic (chronic) hyponatremia, infusions of hyper-
tonic saline should have priority over vaptan.30 This is an
area of significant uncertainty. It has been pointed out that
3% NaCl may correct hyponatremia too quickly,31 or it may
occasionally lead to pulmonary edema in SIAD(H). On the
other hand, we have personal experience (PAG) that SIAD(H)-
related severe symptomatic hyponatremia is a rewarding
indication for vaptan. Thus, in the absence of a trial comparing
fluid restriction plus 3% saline with vaptans in severe
symptomatic hyponatremia, we do not have a database to
make specific recommendations for or against vaptans.
Taken together, there is considerable uncertainty at
present as to which symptoms, which setting, and what
degree of severity of a hyponatremia should be considered
indications for vaptan treatment.
IT IS NOT PROVEN THAT VAPTANS SAVE MONEY
In a study of chronic heart failure termed EVEREST,11
patients receiving tolvaptan were able to leave the hospital
B2 days earlier than control patients. It was concluded that
tolvaptan could shorten hospitalization and save money. Was
this because of better treatment of hyponatremia? Not
automatically, because EVEREST was a study of mostly
normonatremic heart failure and not one primarily of
Kidney International (2011) 80, 594–600 595
PA Gross et al.: Vaptans and the treatment of hyponatremia rev iew
hyponatremia. Another publication used computer modeling
to calculate the annual cost of hyponatremia to the US
health-care system.32 The study came up with an amount of
1.6 to 3.6 billion US dollars.32 These are staggering figures. It
would be a major achievement if these amounts of money
could be saved. However, we lack a study with vaptans
proving that they actually would. Skepticism also applies to
the following work: a retrospective analysis by Shea et al.33
Table 1 | Overview of major reported studies of the use of vaptans in different hyponatremic states
Study; reference End point
Number and
kind of patients
included; duration
of study
Study
design Main results
(1) A vasopressin receptor
antagonist improves serum
sodium concentration in
patients with hyponatremia15
Efficacy and safety of
lixivaptan in euvolemic and
hypervolemic hyponatremia
n=44, with
hyponatremia;
7 days
RCT Lixivaptan appeared effective and safe in
correcting hyponatremia. High doses risked
producing significant dehydration.
(2) Therapy of hyponatremia
in cirrhosis with lixivaptan16
Efficacy of lixivaptan in
hyponatremia of cirrhosis
n=60, with
hyponatremia;
7 days
RCT Lixivaptan was effective in improving the
hyponatremia of cirrhosis.
(3) Vasopressin blockade
with tolvaptan in chronic
heart failure17
Short-term effects of
tolvaptan in chronic
heart failure
n=254, with normo-
and hyponatremia;
25 days
RCT Tolvaptan decreased the body weight by
0.84 kg and improved hyponatremia.
(4) Tolvaptan in patients
hospitalized with worsening
heart failure18
Short-term and
intermediate effects
of tolvaptan
n=310, with normo-
and hyponatremia;
60 days
RCT At 24 h, body weight decreased by 1.4 kg versus
placebo. At 60 days, no difference in worsening
heart failure.
(5) Aquaretic effect of
lixivaptan in chronic
heart failure19
Short-term renal effects
of lixivaptan
n=42, with normo-
and hyponatremia;
24 h
RCT Lixivaptan, 400mg, increased aquaresis by
2.1 l and raised the serum sodium significantly.
(6) Conivaptan, a V1A/V2
antagonist in euvolemic and
hypervolemic hyponatremia14
Efficacy and safety
of (oral) conivaptan
n=74, with
hyponatremia;
5 days
RCT Conivaptan increased serum sodium in a
dose-dependant manner. Headache, hypertension,
nausea, and constipation were noted as side effects.
(7) Long-term treatment
of hyponatremia in SIADH
with satavaptan20
Efficacy and safety
of satavaptan
n=18, with
hyponatremia;
12 months or longer
Open-label
observation
The improvement of the serum sodium was
maintained over the duration of 12 months
and was safe.
(8) Tolvaptan for
hyponatremia12
Improvement of
hyponatremia with
tolvaptan
n=448, with
hyponatremia;
30 days
RCT Tolvaptan was effective in increasing the serum
sodium at days 4 and 30.
(9) EVEREST clinical
status trials21
Short-term effects of
tolvaptan on congestion
of heart failure
n=4133, with normo-
and hyponatremia;
7 days
RCT Greater improvement of congestion with tolvaptan
than with placebo. More weight loss on day 7 with
tolvaptan (3.3 kg) than with placebo (2.7 kg).
(10) Intravenous conivaptan
in euvolemic and
hypervolemic hyponatremia22
Efficacy and tolerability
of i.v. conivaptan
n=84, with
hyponatremia;
4 days
RCT Four days of i.v. conivaptan significantly increased
serum sodium. Adverse events were injection site
phlebitis and postural hypotension.
(11) EVEREST outcome trial11 All-cause mortality in
cardiac failure receiving
tolvaptan
n=4133, with normo-
and hyponatremia;
9.8 months
RCT Mortality in treated and untreated patients
was comparable.
(12) Effects of satavaptan
on ascites and serum
sodium in cirrhosis with
hyponatremia23
Effects on ascites and
hyponatremia in cirrhosis
n=110, with
hyponatremia;
14 days
RCT Satavaptan improved hyponatremia and the control
of ascites.
(13) Oral conivaptan in
euvolemic and hypervolemic
hyponatremia24
Efficacy and safety of oral
conivaptan in hyponatremia
n=83, with
hyponatremia;
5 days
RCT Oral conivaptan was effective and increased
serum sodium in patients with euvolemic or
hypervolemic hyponatremia.
(14) Intravenous conivaptan
for the treatment
of hyponatremia13
Clinical experience using
i.v. conivaptan
n=18, with
hyponatremia;
72 h
Retrospective
analysis
Lower serum sodium at baseline and higher
eGFR were correlated with larger response
to conivaptan.
(15) SALTWATER25 Safety and efficacy of
tolvaptan during long-term
treatment
n=111, with
hyponatremia;
1.5 years
Open-label
observation
Normonatremia was maintained throughout.
Only 1 patient developed hypernatremia.
Abbreviations: eGFR, estimated glomerular filtration rate; i.v., intravenous; RCT, randomized controlled trial.
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indicated that the use of resources by patients with
hyponatremia was B100% higher than that by matched
patients with normonatremia. This is impressive. But is it
guaranteed that normalization of natremia with vaptan will
take the excessive expense away? We will not know unless the
question is tested prospectively in a study. Yet another issue
related to cost has to do with discontinuation of vaptan
therapy. Unless the underlying condition has been corrected,
hyponatremia is likely to return. This could cause recurrent
morbidity and expense, making the use of vaptan proble-
matic. Together, do vaptans save money when used to treat
hyponatremia? There are suggestive, although retrospective,
data; we are lacking prospective work.
IT IS DIFFICULT TO JUSTIFY THE COST OF LONG-TERM
VAPTAN TREATMENT
Otsuka (Otsuka Pharmaceutical, Osaka, Japan) recommends
a standard regimen for hyponatremia of 15 or 30 mg of
tolvaptan once daily p.o. In Germany, a tablet (15 or 30 mg
alike) is presently sold for 103h, roughly equivalent to US
$130. In the United States, a tablet reportedly costs
approximately US $244. In other words, a month of vaptan
treatment—if that was ever to be given to a patient—could
cost as much as 3150h in Europe or US $7200 in the United
States (These high amounts may primarily apply to
hypervolemic hyponatremia. In euvolemic hyponatremia,
treatment costs for vaptans are likely to be lower because
there is an increased sensitivity to vaptan in that setting.)
Such costs are in excess of those for a month of chronic
hemodialysis for instance. Conivaptan therapy is even costlier
than tolvaptan in Europe. There is no published prospective
evidence demonstrating how such costs can be justified
in terms of benefit to the patient and to the health-care
system. It is not known what kind of symptoms a
hyponatremic patient would have to exhibit to justify such
treatment costs.
In fact, considering that the majority of hyponatremic
patients will have mild hyponatremia and will be clinically
oligosymptomatic or asymptomatic, would it not make more
sense to test alternative therapies for chronic hyponatremia in
them like urea? Urea has been used for a long time as an
agent that induces an osmotic diuresis—when given in
sufficient quantities. It may be used orally, by nasogastric
tube, or intravenously. It has been shown that urea is able to
correct hyponatremia in SIAD(H), even when patients were
in intensive care for hyponatremia.34,35 The major advantage
of urea is its very low cost. A potential disadvantage may be
its taste. However, if pharmacological grade urea is used
in quantities of 15–30 g/day or more, it may be dissolved in
orange juice, which will make the taste palatable. A study
comparing urea treatment with vaptan therapy, done in
patients with mild hyponatremia, is probably indicated to
compare the efficacy, the quality-of-life aspects, and the cost
of both treatments in that specific setting.
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Figure 1 | Instability of gait by three patients in hyponatremia (left three panels) and improvement of gait in the same patients
after correction of hyponatremia (right three panels). In each example, the patient was asked to walk from left to right (reprinted from
reference Renneboog et al.27; with permission from Elsevier).
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IT HAS NOT BEEN SHOWN THAT VAPTANS SAVE LIVES
This is an important but controversial issue. The association
of hyponatremia with increased mortality is well documented
in the literature,6–10,36 but its meaning is disputed. Some
interpret this literature to suggest that hyponatremia actually
causes increased mortality. Hence, a few years ago, a finding
from a trial termed ACTIVE in CHF37 met with interest. In a
post hoc analysis of a subgroup of 69 study participants with
hyponatremia (total number of participants: 319, normo-
and hypo-natremic, tolvaptan vs placebo), ACTIVE found
mortality to be significantly lower in those in whom
hyponatremia improved (usually receiving tolvaptan) when
compared with the remainder 69 in whom hyponatremia
remained unchanged (usually receiving placebo). The reduc-
tion of mortality amounted to B50%. This was a post hoc
analysis of a subgroup from a larger trial, and hence there was
a possibility that the results could have been fortuitous.
Subsequently, a randomized controlled trial termed EVER-
EST11 was set up to probe the question of tolvaptan with
respect to mortality more rigorously. EVEREST gave
tolvaptan (30 mg q.d. p.o.) versus placebo for up to 24
months in 4133 patients with cardiac failure. The primary
end point was mortality. However, the resulting mortality
curves for tolvaptan- and placebo-treated patients were not
different from each other (Figure 2).
Another report addressed the role of hyponatremia on
admission for the hospital course and outcome.38 Data were
obtained in a retrospective manner from a large adminis-
trative database representing 198,281 discharges from 39 US
hospitals in 2004 and 2005. Patients with hyponatremia were
older (65.7 vs 61.5 years) and had a higher comorbidity score
(1.8±2.1 vs 1.3±1.8) than their normonatremic counter-
parts. A higher proportion of hyponatremic patients required
intensive care within the first 48 h of hospitalization (17.3 vs
10.9%). Hospital mortality (5.9 vs 3%) and mean length of
stay (8.6 vs 7.2 days) were significantly increased in those
with admission hyponatremia when compared with normo-
natremic patients.
An even more detailed study was reported recently.39
It represents a prospective cohort study of 98 411 hospital
admissions of two teaching hospitals in Boston, MA, between
2000 and 2003. Patients with hyponatremia were older
(67 vs 63.1 years) and had more comorbid conditions
than normonatremic patients (index: 1.9 vs 1.4). Patients
with hyponatremia had an increased risk of death in the
hospital (odds ratio 1.47), at 1 year after discharge (hazard
ratio 1.38), and at 5 years (hazard ratio 1.25). The relation-
ship between hyponatremia and mortality was pronounced
in patients with cardiovascular disease, metastatic cancer,
and musculoskeletal disorders. Resolution of hyponatremia
during hospitalization attenuated the increased mortality risk
conferred by hyponatremia.
These are intriguing studies. Do they clarify whether
patients die from hyponatremia or with hyponatremia? In
our opinion this question cannot be answered at the present
time. Prospective interventional work will eventually have to
resolve this issue.
QUESTIONS ABOUT THE SAFETY OF VAPTAN TREATMENTS
In a recent publication of work reporting the use of
conivaptan in everyday medicine, B50% of treatments
corrected hyponatremia too fast. Treatment regimens had
to be interrupted, halted, or even reversed to prevent adverse
outcomes.13 One out of 18 treated patients experienced
transient symptomatic hypotension and required a bolus of
250 ml of normal saline. Two out of four patients receiving
conivaptan through a peripheral venous line had injection
site reactions, whereas 14 patients receiving conivaptan
through central venous catheters had no such reactions.
Two patients met the criteria for a significant rise in serum
creatinine although their peak serum creatinine remained
o1.0 mg/dl. One patient fulfilled the criteria for azotemia
and his blood urea nitrogen level rose from 22 to 40 mg/dl.13
Although these observations may be consequences of the
efficiency of conivaptan, they do illustrate that caution is
warranted in using this agent.
In terms of tolvaptan, the manufacturer recommends
beginning treatment with 15 or 30 mg q.d. Our own (PAG)
preliminary experience in SIAD(H) is that 7.5 mg q.d. may
suffice. It is unclear at which time points after the start of a
vaptan therapy, controls of the serum sodium should be done
to provide for safety of the correction rate. Last, there is no
published experience on how to proceed when ‘back-
titration’ of natremia becomes necessary.
Taken together, optimal dosing, monitoring, and adequate
precautions in the use of vaptans should be better defined.
VAPTANS AS A PROPHYLAXIS AGAINST RELAPSE INTO
HYPONATREMIA: IN WHICH PATIENTS WILL IT PAY?
A study termed SALTWATER25 has recently reported safe and
successful long-term tolvaptan treatment in 111 patients with
All-cause mortality
Log-rank test: P=0.76
Peto-Peto-Wilcoxon test: P=0.68
Stratified Peto-Peto-Wilcoxon test: P=0.68
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Figure 2 |Kaplan–Meier analysis of all-cause-mortality in the
EVEREST study. There was no difference in mortality between
tolvaptan- and placebo-treated participants (reproduced from
reference Konstam et al.11; with permission from American
Medical Association; Copyright 2007 American Medical
Association. All rights reserved).
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euvolemic and hypervolemic hyponatremia over B2 years.
Hypernatremia leading to discontinuation was noted in a
single patient only. SALTWATER probably proved the
principle, but will it work in everyday medicine as well and
will it be as safe as under scientific observation? In addition,
what frequency of naturally occurring relapses into hypona-
tremia that lead to hospital admission would be required to
justify chronic vaptan treatment in such patients? What kind
of chronic symptoms, significantly lowering the quality of life
should a hyponatremic patient exhibit for the same reasons?
Clearly, more data are necessary about this possible
indication before it can be generally recommended.
ARE WE CRITICIZING VAPTANS UNFAIRLY?
It could be said that our proposals are asymmetrical and
biased, as we do not postulate comparable trials to be done
for the other measures to treat hyponatremia, such as fluid
restriction or lithium treatment, for instance. We would
disagree. Besides being of some vintage, these much older
approaches do not qualify for being directed, highly potent,
specifically designed, and pathophysiologically focused novel
treatments of hyponatremia. But vaptans do. Hence, the
usual present standard of scrutiny applies more to vaptans
than to the other methods.
CONCLUDING COMMENTS
Based on the foregoing we believe that research into the
appropriate indications for vaptans is urgently needed. There
is significant uncertainty at this time concerning when, how,
and for how long to use vaptans. These issues may be
resolvable in future randomized controlled trials. At the
present time, for the reasons presented here, vaptans cannot
(yet?) constitute the mainstay of therapy in hyponatremia.
Having said this, we would like to add that we (PAG) use
vaptans in the permitted settings. We find them to be of
advantage to physicians and patients alike—if great caution is
applied in terms of frequent controls and dosing and if
demonstrable symptoms are present.
To return to the car dealer business, the metaphor that we
used in the beginning of this communication; we did not
stick to our guns, instead we got that great new car. It
surprised us in several ways: the actual speed differed at times
from what it was meant to be; we were not always sure
whether we should take that car or walk by our feet; the
brakes did not always work as anticipated—but then the
maintenance turned out cheaper than expected. And so on.
Are these nothing but teething problems? Possible, more time
and studies will be needed to tell. Do not give up, stay tuned.
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